Docoh
Loading...

MMSI Merit Medical Systems

Founded in 1987, Merit Medical Systems, Inc. is a leading manufacturer and marketer of proprietary disposable medical devices used in interventional, diagnostic and therapeutic procedures, particularly in cardiology, radiology, oncology, critical care and endoscopy. Merit serves client hospitals worldwide with a domestic and international sales force and clinical support team totaling in excess of 500 individuals. Merit employs approximately 6,000 people worldwide with facilities in South Jordan, Utah; Pearland, Texas; Richmond, Virginia; Rockland, Massachusetts; Aliso Viejo, California; Maastricht and Venlo, The Netherlands; Paris, France; Galway, Ireland; Beijing, China; Tijuana, Mexico; Joinville, Brazil; Ontario, Canada; Melbourne, Australia; Tokyo, Japan; Reading, United Kingdom; Johannesburg, South Africa; and Singapore.

Company profile

Ticker
MMSI
Exchange
Website
CEO
Fred Lampropoulos
Employees
Incorporated
Location
Fiscal year end
SEC CIK
IRS number
870447695

MMSI stock data

(
)

Calendar

7 May 21
4 Aug 21
31 Dec 21
Quarter (USD)
Mar 21 Dec 20 Sep 20 Jun 20
Revenue
Cost of revenue
Operating income
Operating margin
Net income
Net profit margin
Cash on hand
Change in cash
Diluted EPS
Annual (USD)
Dec 20 Dec 19 Dec 18 Dec 17
Revenue
Cost of revenue
Operating income
Operating margin
Net income
Net profit margin
Cash on hand
Change in cash
Diluted EPS

Financial data from company earnings reports.

Date Owner Security Transaction Code Indirect 10b5-1 $Price #Shares $Value #Remaining
17 Jun 21 Anderson Jill Common Stock, No Par Value Grant Aquire A No No 0 2,914 0 7,102
17 Jun 21 Ward Lynne Common Stock, No Par Value Grant Aquire A No No 0 2,914 0 7,102
17 Jun 21 Millner F. Ann Common Stock, No Par Value Grant Aquire A No No 0 2,914 0 21,026
17 Jun 21 Carpenter Lonny J Common Stock, No Par Value Grant Aquire A No No 0 2,914 0 7,472

Data for the last complete 13F reporting period. To see the most recent changes to ownership, click the ownership history button above.

96.0% owned by funds/institutions
13F holders
Current Prev Q Change
Total holders 226 224 +0.9%
Opened positions 32 40 -20.0%
Closed positions 30 22 +36.4%
Increased positions 67 71 -5.6%
Reduced positions 97 85 +14.1%
13F shares
Current Prev Q Change
Total value 3.79B 3.2B +18.6%
Total shares 53.78M 55.48M -3.1%
Total puts 24.5K 14.9K +64.4%
Total calls 20K 24.8K -19.4%
Total put/call ratio 1.2 0.6 +103.9%
Largest owners
Shares Value Change
BLK Blackrock 7.82M $468.39M +2.8%
Vanguard 5.62M $336.57M +2.6%
ArrowMark Colorado 4.3M $257.41M -5.0%
Starboard Value 3.74M $223.88M -6.2%
William Blair Investment Management 3.48M $208.2M +2.6%
Conestoga Capital Advisors 2.33M $139.61M +12.9%
STT State Street 1.89M $112.88M -1.4%
Dimensional Fund Advisors 1.57M $94.2M -6.6%
MCQEF Macquarie 1.4M $83.77M -5.9%
Aristotle Capital Boston 1.39M $83.37M -4.5%
Largest transactions
Shares Bought/sold Change
Nuance Investments 931.91K -898.7K -49.1%
Loomis Sayles & Co L P 759.37K +759.37K NEW
Soltis Investment Advisors 5.5K -660.82K -99.2%
Norges Bank 0 -530.46K EXIT
Frontier Capital Management 326.92K -424.19K -56.5%
Conestoga Capital Advisors 2.33M +266.62K +12.9%
Starboard Value 3.74M -245.3K -6.2%
GS Goldman Sachs 587.1K -230.6K -28.2%
WHG Westwood 999.26K +228.71K +29.7%
ArrowMark Colorado 4.3M -225.16K -5.0%

Financial report summary

?
Management Discussion
  • Sales for the three-month period ended March 31, 2021 increased by 2.2%, or approximately $5.4 million, compared to the corresponding period in 2020. Listed below are the sales by product category within each of our financial reporting segments for the three-month periods ended March 31, 2021 and 2020 (in thousands, other than percentage changes):
  • Cardiovascular Sales. Our cardiovascular sales for the three-month period ended March 31, 2021 were approximately $241.0 million, up 2.3% when compared to the corresponding period of 2020 of approximately $235.5 million. Sales for the three-month period ended March 31, 2021 were favorably affected by increased sales of:
  • Endoscopy Sales. Our endoscopy sales for the three-month period ended March 31, 2021 were approximately $7.9 million, down (0.9)%, when compared to sales in the corresponding period of 2020 of approximately $8.0 million. Sales for the three-month periods ended March 31, 2021 were unfavorably affected by deceased sales of the NinePoint NvisionVLE® Imaging System as a result of the suspension of our distribution agreement with NinePoint, offset partially by increased sales of probes and our EndoMAXX® fully covered esophageal stents.
Content analysis
?
Positive
Negative
Uncertain
Constraining
Legalese
Litigous
Readability
H.S. sophomore Avg
New words: added, detailed, Efficacy, Endovascular, enrolled, Graft, half, Human, Innovation, Internationally, KA, marked, MDR, Medallion, Michel, Micro, nitinol, November, occlusion, original, Pivotal, PlugTM, program, repeat, rest, Robert, sensitivity, slight, syringe, tender, uneven, vaccination, Voigt, written
Removed: accelerated, achieve, acquiring, actively, adjustment, alteration, ambulatory, anesthesia, annually, antidilutive, approach, April, Australia, avoid, backlog, Brightwater, calculation, canceled, cancellation, capitalizing, case, catheter, center, certification, clearance, Cloud, collect, comparability, compression, Computing, conform, consolidating, consolidation, consummated, contact, contemplated, contingently, converted, ConvertX, convey, corporate, created, decrease, delayed, Department, depend, desire, difficult, dilutive, direct, disaggregation, disruption, diversion, driven, duration, economy, efficiency, effort, emerge, employee, encourage, environment, escalation, excluded, extent, Fibrovein, final, Fluidx, focused, formal, fracture, health, healthcare, heightening, hope, hospital, hosting, iii, impacting, impediment, implanted, implement, implemented, impose, imposed, incentive, infection, initiated, instituted, investigation, issuable, iv, Jordan, Justice, kit, license, lifted, likelihood, list, managed, mandatory, manufacturing, marketing, Mexico, mitigation, moving, multiplier, nasopharyngeal, navigate, negatively, nephroureteral, obtain, obtained, occur, organization, owner, patient, payout, Pearland, pending, people, performed, personnel, pharmaceutical, postponed, potentially, predict, predicted, presence, prevent, primary, prioritized, private, promotional, public, received, reclassification, recommended, reconciling, reduction, regulatory, replace, replaced, requiring, reserve, respond, responded, responding, response, restricting, resume, retained, retrospective, revised, rounded, safety, salary, satellite, scale, sclerotherapy, SEC, sedation, seeking, smaller, software, specialty, specifically, spread, STD, strain, strict, subpoena, subsequent, substantial, Subtopic, supporting, surfaced, surgery, suspected, suspended, Sustained, swab, telecommuting, temperature, testing, threshold, Tijuana, transport, treat, UK, uncertain, uncertainty, unclear, undiscounted, upfront, ureter, Utah, vertebral, vi, vii, voting, work